UTRECHT, Nederland–(BUSINESS WIRE)– AM Pharma BV, een opkomende leider die zich richt op het ontwikkelen van therapieën voor ernstige medische aandoeningen, heeft vandaag aangekondigd dat Erik van den Berg, de Chief Executive Officer van het bedrijf, en Lars Boesgaard, Chief Financial Officer, zullen deelnemen op de volgende beleggersconferenties:

• Kempen’s 40e jaarlijkse Life Sciences Virtual Crossover Conference op donderdag 6 januari 2022. Het bedrijf zal beleggersbijeenkomsten houden, die kunnen worden aangevraagd via Kempen.
• HC Wainwright’s BioConnect Virtual Conference op maandag 10 januari 2022 om 7.00 uur Eastern Time.

De HC Wainwright-presentatie zal beschikbaar zijn op het gedeelte Investors van de website van het bedrijf op www.am-pharma.com. Een herhaling van de webcast wordt gearchiveerd en blijft 90 dagen na het evenement beschikbaar.

AM Pharma to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands–(BUSINESS WIRE)– AM Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, the Company’s Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, will participate in the following investor conferences:

• Kempen’s 40^th Annual Life Sciences Virtual Crossover Conference on Thursday, January 6, 2022. The Company will be conducting investor meetings, which can be requested through Kempen.
• H.C. Wainwright’s BioConnect Virtual Conference on Monday, January 10, 2022 at 7:00 a.m. Eastern Time.

The H.C. Wainwright presentation will be available on the Investors section of the Company’s website at www.am-pharma.com. A replay of the webcast will be archived and available for 90 days following the event.

About AM-Pharma

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals. Find out more about us online at: www.am-pharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005813/en/

Contacts

Investors:
Argot Partners

+1 212.600.1902

AMPharma@argotpartners.com

Media:
Trophic Communications

Gretchen Schweitzer or Sophia Hergenhan

+49.89.238.877.30

Am-pharma@trophic.eu